Case Report on Denosumab Triggering Osteonecrosis in Osteoporosis Patient
Author Information
Author(s): Száraz Dávid, Peřina Vojtěch, Treglerová Jana, Macháček Ctirad, Zendulka Ondřej, Bořilová Linhartová Petra
Primary Institution: University Hospital Brno, Czechia
Hypothesis
Can a single low dose of denosumab trigger medication-related osteonecrosis of the jaw (MRONJ) in patients previously treated with bisphosphonates?
Conclusion
A single low dose of denosumab can trigger MRONJ in patients with a history of bisphosphonate therapy.
Supporting Evidence
- Only six similar cases of MRONJ after a single low dose of denosumab have been reported.
- The patient developed MRONJ stage III three months after receiving denosumab.
- Previous treatment with bisphosphonates may have contributed to the rapid onset of MRONJ.
Takeaway
This study shows that even one shot of a medicine called denosumab can cause serious jaw problems in older people who have taken other medicines for bone health.
Methodology
Case report and literature review.
Potential Biases
Potential bias due to the retrospective nature of the literature review.
Limitations
The findings are based on a single case and may not be generalizable.
Participant Demographics
An 83-year-old female patient with osteoporosis and multiple comorbidities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website